APE chemotherapy for children with relapsed Hodgkin disease: A pediatric oncology group trial

Pediatric Blood and Cancer

Volumn 46, Issue 3, 2006, Pages 320-324

  Wimmer, Robert S ^a   Chauvenet, Allen R ^a   London, Wendy B ^a   Villaluna, Doojduen ^a   De Alarcon, Pedro A ^a   Schwartz, Cindy L ^a,b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b HASBRO CHILDREN'S HOSPITAL   (United States)

Author keywords

Cisplatin; Cytosine arabinoside; Etoposide; Hodgkin disease; Recurrent disease

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; ETOPOSIDE;

ADOLESCENT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; MYCOSIS; NAUSEA; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 32044471088     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20563     Document Type: Article

References (21)

1. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin's disease-Finding the balance between cure and late effects. Cancer J Sci Am 1999;5:325-333.
2. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982;9:21-35.
3. Devita VT Jr, Serpick AA, Carbone PP. Combination therapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
4. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
5. Ekert H, Waters KD, Smith PJ, et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol 1988;6:1845-1850.
6. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994;12:1169-1176.
7. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161-171.
8. Anselmo AP, Meloni G, Cavalieri E, et al. Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 2000;79:79-82.
9. Enblad G, Hagberg H, Gustavsson A, et al. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: A prospective study. Eur J Haematol 1998;60:166-171.
10. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
11. Brandwein JM, Callum J, Sutcliffe SB, et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990;5:99-103.
12. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-402.
13. Cabanillas F, Velasquez WS, McLaughlin P, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 1988;25:47-50.
14. Silverman L, Jones R, Norton L, et al. 1: Combination chemotherapy for refractory lymphoma with cytosine arabinoside, cisplatin, and etoposide: APE. Proc Am Soc Clin Oncol 1984;3:246 (abstr 963).
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J AM Stat Assoc 1958;53:457-481.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. JRSSA 1972;135:185-198.
17. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New Jersey: John Wiley and Sons; 1980.
18. Krishnan A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000;95:1588-1593.
19. Trippett TM, De Alarcon P, London W, et al. A pilot study of re-induction chemotherapy with ifosfamide, and vinorelbine (IV) in children with refractory/relapsed Hodgkin Disease, AHOD00P1. Eur J Haematol 2004;73:74.
20. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
21. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and 1-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001;19:2390-2396.